Theolytics
Develops oncolytic adenovirus immunotherapies for patients with solid tumours and cancers of high unmet need
Highlights
- New on EvolcAdded 2026-11-01
About Theolytics
Theolytics develops systemically deliverable oncolytic immunotherapies based on adenoviruses. Its Adenovo platform screens viral variants to identify candidates designed to target cancer cells and tumour-supporting stroma; THEO-260 is its lead programme.
The company was founded in 2017 as an Oxford University spin-out and is headquartered in Oxford, United Kingdom. Its programmes include clinical development of THEO-260.
Product: Adenovo viral discovery platform and oncolytic adenovirus immunotherapy candidates, including lead programme THEO-260.
Jobs at Theolytics
Leadership
- David Apelian · CEO / CMOSource: company website
- Margaret Duffy · CSO and Co-FounderSource: company website
- Luke Harris · Head of FinanceSource: company website
More biotech & pharma companies
Theramex
Specialty pharmaceuticals for women’s health, including contraception, fertility, menopause and osteoporosis treatmentsRemote-friendlyTithonia Group
Specialty pharma group that runs a medicine licensing and distribution platform and product brands for prescribers and patients in EuropeNew on EvolcTitian Software
Sample management software for life science labs, including pharma, biotech, CROs and biobanksNew on EvolcRemote-friendlyTiziana Life Sciences
Clinical-stage biotech developing intranasal and fully human antibody immunotherapies for multiple sclerosis, Alzheimer's and ALSNew on EvolcTorrent Pharma (UK)
Distributes generic prescription medicines to UK pharmacies, wholesalers and hospitalsNew on EvolcRemote-friendlyTozaro
Synthetic Smart Polymer affinity ligands for purifying viral vectors and biologics, for cell and gene therapy manufacturersNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Frontend frameworks
- Next.jsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- ReactMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Related technologyimplied by Next.js
Hosting
- VercelHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-vercel-id
- Response headerx-vercel-id
- Response headerx-vercel-id
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.